FERAS ALQAHTANI

Therapeutic Focus: Cardiovascular (CVD)

• Surpassed targets: 152% for Vastarel and 137% overall line YTD in 2024.
• Opened private sector access for Lipocomb, expanding prescriber base.
• Built strong relationships with institutions like Fakeeh, Erfan, IMC, and HMG.
• Achieved DPOs at Saudi Air Hospital and KFAFH, securing long-term product adoption.
• Delivered field insights to marketing, supporting cross-functional strategy alignment.

Therapeutic Focus: Gastroenterology

• Achieved 112% of annual sales target in 2023.
• Successfully launched OMIZ PLUS, developing rapid uptake across key accounts.
• Maintained strong clinical credibility with HCPs, fostering trust and brand loyalty.
• Provided detailed post-call analysis to refine customer strategies and increase engagement impact.
• Increasing the market share of OMIZ key account such as MMC, Aladwani and Bashrahil

• Worked under the guidance of a pharmacist to prepare compounds and dispense medications.
• Observed clinical guidelines to maintain the optimal outcome.
• Collaborated with external healthcare teams for positive patient care continuity.